MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors
RNA-seq (gene expression) · mouse · 26 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 26 samples: 9 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE276571_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1157863 and SRA study SRP531166. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 26 samples.
How we read this: 9 replicated groups read from 26 sample titles; they account for 26 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8502235 MC38/gp100 DMSO_1 MC38/gp100 DMSO
- GSM8502236 MC38/gp100 DMSO_2 MC38/gp100 DMSO
- GSM8502237 MC38/gp100 DMSO_3 MC38/gp100 DMSO
- GSM8502238 MC38/gp100 0.5 μM GSK3326595_1 MC38/gp100 0.5 μM GSK33…
- GSM8502239 MC38/gp100 0.5 μM GSK3326595_2 MC38/gp100 0.5 μM GSK33…
- GSM8502240 MC38/gp100 0.5 μM GSK3326595_3 MC38/gp100 0.5 μM GSK33…
- GSM8502241 MC38/gp100 0.5 μM MRTX1719_1 MC38/gp100 0.5 μM MRTX1…
- GSM8502242 MC38/gp100 0.5 μM MRTX1719_3 MC38/gp100 0.5 μM MRTX1…
- GSM8502243 MC38/gp100 Mtap KO DMSO_1 MC38/gp100 Mtap KO DMSO
- GSM8502244 MC38/gp100 Mtap KO DMSO_2 MC38/gp100 Mtap KO DMSO
- GSM8502245 MC38/gp100 Mtap KO DMSO_3 MC38/gp100 Mtap KO DMSO
- GSM8502246 MC38/gp100 Mtap KO 0.5 μM GSK3326595_1 MC38/gp100 Mtap KO 0.5 …
- GSM8502247 MC38/gp100 Mtap KO 0.5 μM GSK3326595_2 MC38/gp100 Mtap KO 0.5 …
- GSM8502248 MC38/gp100 Mtap KO 0.5 μM GSK3326595_3 MC38/gp100 Mtap KO 0.5 …
- GSM8502249 MC38/gp100 Mtap KO 0.5 μM MRTX1719_1 MC38/gp100 Mtap KO 0.5 …
- GSM8502250 MC38/gp100 Mtap KO 0.5 μM MRTX1719_2 MC38/gp100 Mtap KO 0.5 …
- GSM8502251 MC38/gp100 Mtap KO 0.5 μM MRTX1719_3 MC38/gp100 Mtap KO 0.5 …
- GSM8502252 T cell DMSO_1 T cell DMSO
- GSM8502253 T cell DMSO_2 T cell DMSO
- GSM8502254 T cell DMSO_3 T cell DMSO
- GSM8502255 T cell 0.5 μM GSK3326595_1 T cell 0.5 μM GSK3326595
- GSM8502256 T cell 0.5 μM GSK3326595_2 T cell 0.5 μM GSK3326595
- GSM8502257 T cell 0.5 μM GSK3326595_3 T cell 0.5 μM GSK3326595
- GSM8502258 T cell 0.5 μM MRTX1719_1 T cell 0.5 μM MRTX1719
- GSM8502259 T cell 0.5 μM MRTX1719_2 T cell 0.5 μM MRTX1719
- GSM8502260 T cell 0.5 μM MRTX1719_3 T cell 0.5 μM MRTX1719
- GSE64102 Improved antitumor activity of immunotherapy combined with BRAF and MEK inhibitors in BRAFV600E mutant melanoma 13 samples shares inhibitors, antitumor, activity
- GSE301030 Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular Carcinoma 54 samples shares cell-mediated, enhance
- GSE295646 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in acute myeloid leukaemia [mouse RNA-seq] 20 samples shares inhibitors, enhance
- GSE304654 Engineered miR-122 inhibitors enhance endothelial mitochondrial efficiency and improve vascular function 16 samples shares inhibitors, enhance
- GSE274479 Non-Canonical PRC1.1 is required for the activity of Menin-MLL1 Inhibitors in NUP98-Rearranged AML [RNA-seq] 15 samples shares inhibitors, activity
- GSE309596 Combination of PARP and KRASG12D Inhibitors Enhances Therapeutic Efficacy by Exploiting Vulnerabilities(scRNA) 12 samples shares inhibitors, enhance
- GSE297753 MEK Inhibitors Enhance post-radiation anti-tumor Immunity in KRAS-Mutant Lung Cancer 12 samples shares inhibitors, enhance
- GSE236346 Piezo2 promotes resistance to radiation by suppressing CD8+ T cell-mediated antitumor immunity via IRF-1/IL-15 signaling 12 samples shares cell-mediated, antitumor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.